JP2024506329A - 複素環式化合物およびその使用 - Google Patents
複素環式化合物およびその使用 Download PDFInfo
- Publication number
- JP2024506329A JP2024506329A JP2023547848A JP2023547848A JP2024506329A JP 2024506329 A JP2024506329 A JP 2024506329A JP 2023547848 A JP2023547848 A JP 2023547848A JP 2023547848 A JP2023547848 A JP 2023547848A JP 2024506329 A JP2024506329 A JP 2024506329A
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- cycloalkyl
- heterocycloalkyl
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147713P | 2021-02-09 | 2021-02-09 | |
| US202163147712P | 2021-02-09 | 2021-02-09 | |
| US63/147,712 | 2021-02-09 | ||
| US63/147,713 | 2021-02-09 | ||
| US202163166224P | 2021-03-25 | 2021-03-25 | |
| US63/166,224 | 2021-03-25 | ||
| US202163176866P | 2021-04-19 | 2021-04-19 | |
| US63/176,866 | 2021-04-19 | ||
| US202163191910P | 2021-05-21 | 2021-05-21 | |
| US63/191,910 | 2021-05-21 | ||
| PCT/US2022/015874 WO2022173870A1 (en) | 2021-02-09 | 2022-02-09 | Heterocyclic compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506329A true JP2024506329A (ja) | 2024-02-13 |
| JP2024506329A5 JP2024506329A5 (cg-RX-API-DMAC7.html) | 2025-02-19 |
Family
ID=82837902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547848A Withdrawn JP2024506329A (ja) | 2021-02-09 | 2022-02-09 | 複素環式化合物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240254129A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291199A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024506329A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022220678A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3207854A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022173870A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510207A (ja) * | 2021-03-12 | 2024-03-06 | ブリストル-マイヤーズ スクイブ カンパニー | Kras阻害剤 |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| JP2024517693A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 2-アミノベンゾチアゾール化合物及びその使用方法 |
| JP2024520000A (ja) * | 2021-05-24 | 2024-05-21 | 上海瓔黎薬業有限公司 | 含窒素複素環化合物、その製造方法及び使用 |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| CA3191279A1 (en) | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| WO2022135470A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN115141215B (zh) * | 2021-03-30 | 2023-09-15 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| WO2023284881A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| JP2024532735A (ja) * | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| WO2023020519A1 (en) * | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | 1, 4-oxazepane derivatives and uses thereof |
| WO2023039240A1 (en) * | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| US20260200925A1 (en) * | 2021-11-24 | 2026-07-16 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| EP4405337A4 (en) * | 2021-11-30 | 2025-11-26 | Beta Pharma Inc | Fused pyrimidine derivatives as kras oncoprotein inhibitors |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2023137223A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| WO2023138583A1 (zh) * | 2022-01-21 | 2023-07-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| IL314486A (en) * | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | Quinazoline compounds inhibit PAN-KRAS |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025508702A (ja) * | 2022-02-16 | 2025-04-10 | アムジエン・インコーポレーテツド | キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023172737A1 (en) | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| JP2025510656A (ja) * | 2022-03-24 | 2025-04-15 | ベイジーン スウィッツァーランド ゲーエムベーハー | 複素環式化合物、その組成物、及びそれらを用いた治療方法 |
| US20240109918A1 (en) * | 2022-05-04 | 2024-04-04 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117327102B (zh) * | 2022-06-30 | 2026-04-28 | 重庆华森英诺生物科技有限公司 | Kras抑制剂、其制备方法及应用 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024008179A1 (en) * | 2022-07-07 | 2024-01-11 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| TW202426451A (zh) * | 2022-08-24 | 2024-07-01 | 大陸商泰勵生物科技(上海)有限公司 | 具有抗kras突變腫瘤活性的化合物 |
| EP4577214A2 (en) * | 2022-08-26 | 2025-07-02 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras proteins |
| WO2024045066A1 (en) * | 2022-08-31 | 2024-03-07 | Nikang Therapeutics, Inc. | Alkylidene carbamate as kras inhibitors |
| WO2024054926A1 (en) * | 2022-09-07 | 2024-03-14 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
| WO2024054625A2 (en) * | 2022-09-08 | 2024-03-14 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway |
| WO2024056063A1 (zh) * | 2022-09-16 | 2024-03-21 | 南京明德新药研发有限公司 | 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物 |
| WO2024061365A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都奥睿药业有限公司 | 嘧啶并环类化合物及其制备方法与用途 |
| WO2024063576A1 (ko) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Kras 저해 물질로서 신규한 퀴나졸린 화합물 |
| CN117917416A (zh) | 2022-10-21 | 2024-04-23 | 上海领泰生物医药科技有限公司 | Kras g12d降解剂及其制备方法和应用 |
| EP4631942A1 (en) | 2022-10-21 | 2025-10-15 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Pan-kras degrading agent, and preparation method therefor and use thereof |
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| CN118772151A (zh) * | 2023-04-04 | 2024-10-15 | 泰励生物科技(上海)有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2024238633A2 (en) * | 2023-05-15 | 2024-11-21 | Mirati Therapeutics, Inc. | Kras g12s and g12c inhibitors |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| EP4735451A1 (en) | 2023-06-30 | 2026-05-06 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025019823A1 (en) * | 2023-07-20 | 2025-01-23 | Merck Sharp & Dohme Llc | Small molecule protein degraders of kras g12d mutant |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| KR20260054710A (ko) | 2023-08-17 | 2026-04-22 | 트리라인 바이오사이언시스, 인크. | 스피로시클릭 디히드로피라노피리미딘 KRas 저해제 |
| AU2024337016A1 (en) * | 2023-09-08 | 2026-04-16 | Tyligand Bioscience (Shanghai) Limited | Ras inhibitor |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| KR20260084633A (ko) | 2023-10-10 | 2026-06-05 | 청두 하이퍼웨이 파마슈티컬스 컴퍼니 리미티드 | 축합 고리 화합물 및 kras 억제제로서의 응용 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| TW202545934A (zh) * | 2024-02-05 | 2025-12-01 | 日商安斯泰來製藥股份有限公司 | 包含具有突變kras蛋白分解誘導作用之雜環化合物的抗體藥物複合體 |
| AU2025218254A1 (en) * | 2024-02-06 | 2026-07-23 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025218811A1 (zh) * | 2024-04-19 | 2025-10-23 | 领泰生物医药(绍兴)有限公司 | pan-KRAS靶向蛋白降解剂及其制备方法和应用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| WO2020097537A2 (en) * | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| WO2020146613A1 (en) * | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2022076917A1 (en) * | 2020-10-08 | 2022-04-14 | Kumquat Biosciences Inc. | Modulators of cell proliferation and uses thereof |
| US20240417412A1 (en) * | 2021-08-10 | 2024-12-19 | Amgen Inc. | Heterocyclic compounds and methods of use |
| EP4389751A1 (en) * | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
-
2022
- 2022-02-09 AU AU2022220678A patent/AU2022220678A1/en not_active Withdrawn
- 2022-02-09 EP EP22753296.7A patent/EP4291199A4/en not_active Withdrawn
- 2022-02-09 JP JP2023547848A patent/JP2024506329A/ja not_active Withdrawn
- 2022-02-09 CA CA3207854A patent/CA3207854A1/en active Pending
- 2022-02-09 WO PCT/US2022/015874 patent/WO2022173870A1/en not_active Ceased
-
2023
- 2023-08-08 US US18/446,017 patent/US20240254129A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510207A (ja) * | 2021-03-12 | 2024-03-06 | ブリストル-マイヤーズ スクイブ カンパニー | Kras阻害剤 |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| JP2024517693A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 2-アミノベンゾチアゾール化合物及びその使用方法 |
| JP2024520000A (ja) * | 2021-05-24 | 2024-05-21 | 上海瓔黎薬業有限公司 | 含窒素複素環化合物、その製造方法及び使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022173870A1 (en) | 2022-08-18 |
| CA3207854A1 (en) | 2022-08-18 |
| EP4291199A1 (en) | 2023-12-20 |
| AU2022220678A1 (en) | 2023-09-21 |
| US20240254129A1 (en) | 2024-08-01 |
| EP4291199A4 (en) | 2025-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022220678A1 (en) | Heterocyclic compounds and uses thereof | |
| US20240109918A1 (en) | Heterocyclic compounds and uses thereof | |
| US11648254B2 (en) | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | |
| US12365676B2 (en) | Heterocyclic compounds and uses thereof | |
| US20240390389A1 (en) | Heterocyclic compounds and uses thereof | |
| EP4389751A1 (en) | Heterocyclic compounds and uses thereof | |
| JP2024521473A (ja) | 抗がん剤として有用な縮合ヘテロアリール化合物 | |
| WO2023141300A1 (en) | Heterocyclic compounds and uses thereof | |
| EP4519274A1 (en) | Heterocyclic compounds and uses thereof | |
| TW202502779A (zh) | 取代的雜芳族胺及其用途 | |
| CN117120058A (zh) | 杂环化合物及其用途 | |
| WO2025059366A1 (en) | Ras inhibitors | |
| TW202523326A (zh) | 雜環及其用途 | |
| WO2022081912A2 (en) | Heterocycles and uses thereof | |
| KR20250004810A (ko) | 대환식 헤테로환 및 이의 용도 | |
| US20240368191A1 (en) | Heterocyclic compounds and uses thereof | |
| WO2025090809A1 (en) | Macrocyclic heterocycles and uses thereof | |
| CN117794940A (zh) | 用作抗癌药剂的稠合杂芳基化合物 | |
| TW202438056A (zh) | 雜環化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250210 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20250701 |